BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 18848860)

  • 1. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
    Lee BH; Kim YK; Park SH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
    Chen CY; Lin TY; Wang CC; Shuai HA
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
    Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
    J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
    Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A
    Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
    Nakajima M; Terao T; Iwata N; Nakamura J
    Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia.
    Sato G; Yoshimura S; Yamashita H; Okamoto Y; Yamawaki S
    Hiroshima J Med Sci; 2012 Dec; 61(4):75-83. PubMed ID: 23342824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
    Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in sexual dysfunction with aripiprazole: a switching or add-on study.
    Mir A; Shivakumar K; Williamson RJ; McAllister V; O'Keane V; Aitchison KJ
    J Psychopharmacol; 2008 May; 22(3):244-53. PubMed ID: 18308789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.